ClinicalTrials.gg
RecruitingNCT04576130DanICDUpdated Jan 27, 2025

A Danish ICD-study in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation

An interventional study of Implantable cardioverter defibrillator in Coronary Artery Disease, Acute Myocardial Infarction and Ventricular Fibrillation, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark — 5 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Rigshospitalet, Denmark.

Planned enrollment
3rd of 15
1,200 · median 331
Started
2020
the only one that year
No phase
14 of 18
5 open now
Registered
14th of 18
by date

Among the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2020, is one of 14 with no phase, and was the 14th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark, or all of them as a file.
02

Study summary

DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.

03

Conditions studied

  • Coronary Artery Disease
  • Acute Myocardial Infarction
  • Ventricular Fibrillation
  • Ventricular Tachycardia, Sustained
  • Out-Of-Hospital Cardiac Arrest

Keywords

  • Revascularization
  • Percutaneous coronary intervention
  • Implantable cardioverter defibrillator
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with CAD and cardiac arrest due to VF/VT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization.
  • Age ≥18 years
  • >35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF.

Exclusion criteria

Exclusion Criteria:

  • Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic cardiomyopathy)
  • Previous CABG within the last 3 months before index hospitalization
  • less than 1 year or severe neurologic outcome
  • Unable or unwilling to give
  • Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    ICD-implantation

    Implantation of an ICD either during admission or within 4 weeks after discharge from index event.

    Device: Implantable cardioverter defibrillator

  • No intervention
    Standard care

    Guideline directed medical therapy

Interventions

  • DeviceImplantable cardioverter defibrillator

    Implantation of an ICD for secondary prevention

    Also known as: ICD

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    The clinical event committee will aim to attribute the cause of death to the underlying disease process rather than the immediate mechanism. Mortality will be classified as cardiovascular and non-cardiovascular.

    Time frame: 5 years

Secondary outcomes

  1. All cause mortality

    Time frame: 1 year

  2. Sudden cardiovascular death

    Cardiovascular death fulfilling the following criteria: * In witnessed cases a change in cardiovascular status with time until death being \<1 hour. * In unwitnessed cases \<24 hours since last seen alive and functioning normal.

    Time frame: 1 year

  3. Cardiovascular death

    Mortality is considered as cardiovascular unless it is clearly attributable to another cause and thus includes: * Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure). * Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease. * All procedure-related deaths, including those related to a complication of the ICD-procedure or treatment for a complication of the procedure. * All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events. * Death of unknown or cardiac cause.

    Time frame: 1 year

Other outcomes

  1. Device revision or replacement due to infection or malfunction

    Explorative outcome

    Time frame: 1 year

  2. Appropriate shock from an ICD (successfully treated VT/VF)

    Explorative outcome

    Time frame: 1 year

  3. Inappropriate shock from an ICD (shock on non-VT/VF)

    Explorative outcome

    Time frame: 1 year

  4. Register-based all cause mortality

    Time frame: 10 years

  5. Register-based sudden cardiovascular death

    Time frame: 5 years

  6. Register-based sudden cardiovascular death

    Time frame: 10 years

  7. Register-based cardiovascular death

    Time frame: 5 years

  8. Register-based cardiovascular death

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Oct 2032, 144 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 144 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2020
First posted
Oct 6, 2020
StartActual
Oct 12, 2020
Primary completionEst.
Oct 2032
CompletionEst.
Oct 2032
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04576130
Responsible party
Reza Jabbari (Principal investigator, MD, PhD, Rigshospitalet, Denmark) — Principal investigator
First posted
Oct 6, 2020
Start date
Oct 12, 2020
Primary completion
Oct 2032 (estimated)
Completion
Oct 2032 (estimated)
Last update
Jan 27, 2025

Study contacts

Reza Jabbari, MD, PhD
Contact
reza.jabbari.02@regionh.dk
+4535455380
Thomas Engstrøm, MD, PhD, DMSc
Contact
thomas.engstroem@regionh.dk
+4535458444
Reza Jabbari, MD, PhD
principal investigator · Rigshospitalet, Denmark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion